tablets Moxifloxacin are appointed at the following indications:

Treatment of the following bacterial infections caused by microorganisms, sensitive to medicament (see the sections "Pharmacological Properties", "Features of Application", "Side reactions"), at patients since 18 years. It is only necessary to appoint moxifloxacin when use of antibacterial agents which usually recommend for initial treatment of the following infections is inexpedient or when the specified treatment was inefficient.

• Acute bacterial sinusitis (diagnosed with high degree of probability).
• Exacerbation of a chronic obstructive disease of lungs, including the bronchitis (diagnosed with high degree of probability).
• Not hospital pneumonia, except for not hospital pneumonia with a heavy course.
• Inflammatory diseases of the bodies of a small pelvis of easy and average degree (including infectious damage of an upper part of a reproductive system at women, including a salpingitis and an endometritis) which are not associated with tubo-ovarian abscess or abscesses of bodies of a small pelvis. Moxifloxacin in the form of tablets is not recommended for application as monotherapy at inflammatory diseases of bodies of a small pelvis of moderate and average degree, but can be applied in a combination with other appropriate antibacterial agents (for example, cephalosporins) through the growing resistance of a moksifloksatsin to Neisseria gonorrhoeae (except for moksifloksatsinrezistentny strains N. gonorrhoeae ) (see the sections "Pharmacological Properties", "Features of Application").

Moxifloxacin in the form of tablets can be applied to the termination of a course of treatment in which starting therapy by a parenteral form of a moksifloksatsin was effective and it is appointed according to such indications:

• not hospital pneumonia;
• complicated infections of skin and hypodermic structures.

for starting treatment of any infections of skin and hypodermic structures or in case of a heavy current of community-acquired pneumonia.

Should pay attention to official instructions for appropriate use of antibacterial agents.

Structure

Active ingredient: moxifloxacin;

1 tablet contains 436.8 mg of a moksifloksatsin of a hydrochloride that corresponds to 400 mg of a moksifloksatsin;

Excipients: lactoses monohydrate, cellulose microcrystalline, sodium of a kroskarmeloz, magnesium stearate, gipromelloza, ferrous oxide red (E 172), macrogoal 4000, titan dioxide (E 171).

Contraindication

Known sensitivity to a moksifloksatsin or other hinolona, or any of medicine excipients.

• Age up to 18 years.
• Pregnancy or period of feeding by a breast.
• Existence in the anamnesis of diseases of the sinews tied with treatment of a hinolonama.

during preclinical and clinical trials after application of a moksifloksatsin observed changes in a heart electrophysiology in the form of lengthening of an interval of QT. Therefore for safety reasons medicine it is contraindicated to patients with:

• congenital or diagnosed acquired lengthening of an interval of QT;
• violation of electrolytic balance, in particular at not corrected hypopotassemia;
• clinically significant bradycardia;
• clinically significant heart failure with reduced fraction of emission of a left ventricle;
• symptomatic arrhythmias in the anamnesis.

Drug should not be used along with other medicines which extend QT interval.

In connection with limited clinical data of use of medicine it is also contraindicated to patients with an abnormal liver function (class C on classification of Chaylda-Pyyu) and to patients with the increased level of Transaminases (is 5 times higher than the upper bound of norm).

Route of administration

Is recommended to be accepted on 1 tablet (400 mg) of a moksifloksatsin a day.

should take the Pill, without chewing, washing down with enough water. The medicament can be taken irrespective of meal time.

Feature of application

Pregnant

It is contraindicated.

Children

Moxifloxacin is contraindicated to children (up to 18 years). The efficiency and safety of application of a moksifloksatsin for children are not established.

Drivers

reaction to moxifloxacin before steering motor transport or to work with other mechanisms.

in case of accidental overdose no specific actions are required for

. In case of overdose it is necessary to be guided by a clinical picture and to carry out symptomatic maintenance therapy and ECG monitoring in connection with a possibility of lengthening of an interval of QT.

Simultaneous use of activated carbon with a dose of a moksifloksatsin of 400 mg will orally lead

to reduction of system availability of medicine more than for 80%. In case of overdose as a result of oral administration of medicine the use of activated carbon at an initial stage of absorption can be effective for prevention to increase in systemic action of a moksifloksatsin.

Side effects

Infectious complications: the superinfection which arose owing to bacterial or fungal resistance, for example, oral or vaginal candidiases.

from nervous system: headache, dizziness.

from heart: lengthening of an interval of QT at patients with a hypopotassemia.

from a digestive tract: nausea, vomiting, abdominal pain, diarrhea.

from a liver and zhelchevyvodya shchy ways: increase in level of Transaminases.

Interaction

Use of a moksifloksatsin in a combination with any of following medicines contraindicated:

• antiarrhytmic medicines of a class _a (for example, quinidine, hydroquinidine, Disopyramidum);
• antiarrhytmic medicines of class III (for example, Amiodaronum, sotalol, dofetilid, ibutilid);
• antipsychotic medicines (for example, fenotiazina, Pimozidum, sertindol, haloperidol, sultoprid);
• tricyclic antidepressants;
• some antimicrobial means (sakvinavir, sparfloksatsin, erythromycin for intravenous administration, pentamidine, antimalarial medicines, in particular galofantrin);
• some antihistamines (terfenadin, astemizol, mizolastin);
• others (tsizaprid, Vincaminum IV, bepridit, difemanit).

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 3 years.